281 related articles for article (PubMed ID: 19071226)
21. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
Lindberg A; Szalai Z; Pullerits T; Radeczky E
Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
[TBL] [Abstract][Full Text] [Related]
22. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients.
Cazzola M; Noschese P; Salzillo A; De Giglio C; D'Amato G; Matera MG
Respir Med; 2005 May; 99(5):524-8. PubMed ID: 15823447
[TBL] [Abstract][Full Text] [Related]
23. Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD.
Cazzola M; Di Perna F; Noschese P; Vinciguerra A; Calderaro F; Girbino G; Matera MG
Eur Respir J; 1998 Jun; 11(6):1337-41. PubMed ID: 9657576
[TBL] [Abstract][Full Text] [Related]
24. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD.
Briggs DD; Covelli H; Lapidus R; Bhattycharya S; Kesten S; Cassino C
Pulm Pharmacol Ther; 2005; 18(6):397-404. PubMed ID: 16179215
[TBL] [Abstract][Full Text] [Related]
25. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action.
Celik G; Kayacan O; Beder S; Durmaz G
Respiration; 1999; 66(5):434-9. PubMed ID: 10516540
[TBL] [Abstract][Full Text] [Related]
26. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study.
Kottakis J; Cioppa GD; Creemers J; Greefhorst L; Lecler V; Pistelli R; Overend T; Till D; Rapatz Gn; Le Gros V; Bouros D; Siafakas N
Can Respir J; 2002; 9(2):107-15. PubMed ID: 11972164
[TBL] [Abstract][Full Text] [Related]
27. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease.
Appleton S; Poole P; Smith B; Veale A; Lasserson TJ; Chan MM
Cochrane Database Syst Rev; 2006 Jul; (3):CD001104. PubMed ID: 16855959
[TBL] [Abstract][Full Text] [Related]
28. Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease.
Vogelmeier C; Magnussen H; LaForce C; Owen R; Kramer B
Ther Adv Respir Dis; 2011 Oct; 5(5):345-57. PubMed ID: 21719531
[TBL] [Abstract][Full Text] [Related]
29. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease.
Cazzola M; D'Amato M; Califano C; Di Perna F; Calderaro E; Matera MG; D'Amato G
Clin Ther; 2002 Apr; 24(4):595-604. PubMed ID: 12017404
[TBL] [Abstract][Full Text] [Related]
30. Onset of bronchodilation with fluticasone/formoterol combination versus fluticasone/salmeterol in an open-label, randomized study.
Aalbers R; Brusselle G; McIver T; Grothe B; Bodzenta-Lukaszyk A
Adv Ther; 2012 Nov; 29(11):958-69. PubMed ID: 23081745
[TBL] [Abstract][Full Text] [Related]
31. Fluticasone/Formoterol combination therapy compared with monotherapy in adolescent and adult patients with mild to moderate asthma.
Pearlman DS; LaForce CF; Kaiser K
Clin Ther; 2013 Jul; 35(7):950-66. PubMed ID: 23870606
[TBL] [Abstract][Full Text] [Related]
32. The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease.
Chapman KR; Arvidsson P; Chuchalin AG; Dhillon DP; Faurschou P; Goldstein RS; Kuipers AF;
Can Respir J; 2002; 9(3):178-85. PubMed ID: 12068339
[TBL] [Abstract][Full Text] [Related]
33. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial.
Calverley PM; Kuna P; Monsó E; Costantini M; Petruzzelli S; Sergio F; Varoli G; Papi A; Brusasco V
Respir Med; 2010 Dec; 104(12):1858-68. PubMed ID: 20965712
[TBL] [Abstract][Full Text] [Related]
34. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD.
O'Donnell DE; Sciurba F; Celli B; Mahler DA; Webb KA; Kalberg CJ; Knobil K
Chest; 2006 Sep; 130(3):647-56. PubMed ID: 16963658
[TBL] [Abstract][Full Text] [Related]
35. An acute bronchodilator test with tiotropium or salmeterol does not allow a subdivision of patients according to responses.
Matera MG; Sanduzzi A; Ponticiello A; Vatrella A; Salzillo A; Cazzola M
Respiration; 2005; 72(5):466-70. PubMed ID: 16210884
[TBL] [Abstract][Full Text] [Related]
36. [Indacaterol--a new hope for maximising bronchodilation?].
Mihălţan F
Pneumologia; 2011; 60(1):21-5. PubMed ID: 21548196
[TBL] [Abstract][Full Text] [Related]
37. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol.
Lipworth BJ; Aziz I
J Allergy Clin Immunol; 1999 Jan; 103(1 Pt 1):88-92. PubMed ID: 9893190
[TBL] [Abstract][Full Text] [Related]
38. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
Calverley P; Pauwels R; Vestbo J; Jones P; Pride N; Gulsvik A; Anderson J; Maden C;
Lancet; 2003 Feb; 361(9356):449-56. PubMed ID: 12583942
[TBL] [Abstract][Full Text] [Related]
39. Formoterol: a review of its use in chronic obstructive pulmonary disease.
Cheer SM; Scott LJ
Am J Respir Med; 2002; 1(4):285-300. PubMed ID: 14720051
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the bronchodilating effects of inhaled formoterol, salmeterol and salbutamol in asthmatic patients.
Grembiale RD; Pelaia G; Naty S; Vatrella A; Tranfa CM; Marsico SA
Pulm Pharmacol Ther; 2002; 15(5):463-6. PubMed ID: 12406669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
